Healthcare, Pharma & Life Sciences

AAAAI Pushes Penicillin Allergy De-Labeling as 90% of Patients Cleared

Image
AAAAI Pushes Penicillin Allergy De-Labeling as 90% of Patients Cleared

Milwaukee – September 23, 2026 -- More than 90% of patients carrying a documented penicillin allergy in their electronic medical records can safely take the drug after clinical evaluation, according to the American Academy of Allergy, Asthma & Immunology (AAAAI), which is marking National Penicillin Allergy Day on September 28 with a push for wider adoption of allergy "de-labeling" protocols.

Inaccurate allergy labels block access to first-line infection treatment

Penicillin remains the most effective therapy for many bacterial infections, yet patients with unverified allergy labels are routinely steered toward alternative antibiotics. The AAAAI states that removing inaccurate labels through evaluation improves patient outcomes, lowers healthcare costs and supports efforts against antimicrobial resistance.

121G Adds AI Anomaly Monitoring to 10Bridge Healthcare Data Platform

Image
121G Adds AI Anomaly Monitoring to 10Bridge Healthcare Data Platform

Carrollton, Ga. – September 23, 2026 -- 121G has added AI Process Anomaly Monitoring to its 10Bridge data acquisition and interoperability platform, giving healthcare organizations automated detection of irregular file and data processing behavior before it disrupts operations.

New tool flags data deviations before they cause integration failures

The capability continuously monitors jobs processed through 10Bridge, automatically identifying transactions, files, or data that fall outside typical processing patterns. When an anomaly surfaces, the system alerts designated users so they can investigate and resolve issues preemptively, rather than after a failure disrupts downstream systems.

Viva-Thera, XtalPi Nominate HIV Drug Candidate in Seven Months

Image
Viva-Thera, XtalPi Nominate HIV Drug Candidate in Seven Months

Boston – September 22, 2026 -- Viva-Thera has nominated a preclinical candidate targeting the membrane-proximal external region (MPER) of HIV-1 gp41, completing discovery and optimization in seven months through a partnership with AI drug-design firm XtalPi (HKEX: 2228). The biotech, incubated and backed by XtalPi as a strategic shareholder, made its public debut disclosing progress across four HIV modalities: vaccines, long-acting small molecules, gene therapy and cell therapy.

XtalPi's AI screened 10 million compounds to isolate five validated hits

Using generative AI, XtalPi navigated a chemical space of approximately 10 million compounds to identify five hits with strong antiviral activity and favorable drug properties. Continuous optimization of these leads drove the program to preclinical candidate nomination within seven months, according to the companies.

ROMTech Targets VA Rural Care Gap With Home Rehab Data

Image
ROMTech Targets VA Rural Care Gap With Home Rehab Data

Brookfield, Conn. – September 22, 2026 -- ROM Technologies Inc. (ROMTech) said its PortableConnect Rehab System can address two structural barriers facing Department of Veterans Affairs knee-replacement patients: distance from rehabilitation sites and fractured coordination between VA and Community Care providers.

Rural Veterans face outsized travel burdens for post-surgical rehabilitation

Approximately 3 million rural Veterans are enrolled in VA health care, and 54% are age 65 or older. A national VA knee-replacement study found 40.8% of patients lived in rural areas, making repeated long-distance travel a barrier to consistent rehabilitation. The VA's 2026 revised budget request includes roughly $2.29 billion for Beneficiary Travel, though the agency does not break out spending attributable to rehabilitation or rural Veterans specifically.

BRIJ Medical Study: Zero Complications in 100 Orthopedic Cases

Image
BRIJ Medical Study: Zero Complications in 100 Orthopedic Cases

San Diego – September 22, 2026 -- BRIJ Medical reported zero documented cases of wound dehiscence, infection, allergic dermatitis, adhesive-related skin injury or wound-related reoperation across a 100-case retrospective study of its Brijjit Force-Modulating Tissue Bridges in sports medicine incision management.

Single-surgeon study spans three years of orthopedic procedures

The study, published in the Journal of Orthopaedic Experience & Innovation (Volume 7, Issue 2), evaluated 100 consecutive outpatient sports medicine procedures performed by a single surgeon, John A. Grotting, MD, between January 2023 and December 2025. Cases spanned ACL, knee, shoulder, elbow and ankle procedures, with co-author Ege Karadag.

RIVANNA Files 100th Patent, Expanding AI Ultrasound IP Estate

Image
RIVANNA Files 100th Patent, Expanding AI Ultrasound IP Estate

Charlottesville, Va. – September 22, 2026 -- RIVANNA has filed its 100th patent, U.S. application #64/080,862, covering an AI-powered ultrasound pathology detection pipeline for automated computer-aided diagnosis on its Accuro XV platform, marking 15 years of continuous intellectual-property development at the medical technology company.

NYCRC Closes $20M Financing for Bronx Health Plaza

Image
NYCRC Closes $20M Financing for Bronx Health Plaza

New York – – September 22, 2026 -- New York City Regional Center (NYCRC) has closed $20 million in New Markets Tax Credit financing to fund construction of an 87,000-square-foot healthcare facility in the South Bronx.

NYCRC deploys portion of $75 million federal tax credit award

The $20 million transaction draws on a $75 million New Markets Tax Credit allocation from the U.S. Department of Treasury to NYC Regional Community Development, an entity managed by NYCRC. To secure the allocation, NYCRC had to demonstrate a track record of directing investment capital into low-income communities.

Health Union, DTC Perspectives Launch Rare Disease Marketing Summit

Image
Health Union, DTC Perspectives Launch Rare Disease Marketing Summit

Philadelphia – September 22, 2026 -- Health Union and DTC Perspectives have launched a strategic partnership to stage an invitation-only executive summit focused on redefining commercial models for rare disease and niche oncology marketing.

Summit convenes senior biopharma marketers in Boston on November 5, 2026

The Rare Marketing Summit: Redefining the Commercial Model for Rare Disease will run from 10:00 AM to 4:00 PM at The Westin Copley Place in Boston, MA, followed by a cocktail reception. Attendance is capped to preserve intimate peer exchange among senior-level biopharma marketing leaders.

CU Anschutz Gets $50M Gift to Build Top CSF Leak Center

Image
CU Anschutz Gets $50M Gift to Build Top CSF Leak Center

Aurora, Colo. – September 22, 2026 -- University of Colorado Anschutz has received an anonymous $50 million gift, one of the largest in campus history, to expand its CSF Leak Program into a world-leading center for diagnosis, treatment and research of cerebrospinal fluid leaks.

Patient survey reveals systemic diagnostic failures across the field

CU Anschutz researchers, working with the Spinal CSF Leak Foundation, conducted the largest patient survey ever done on the condition. Nearly 80% of patients reported being misdiagnosed, seeing a median of more than six clinicians before an accurate diagnosis. More than 60% said long waitlists blocked access to specialized care, forcing many to travel across state lines for treatment.